Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.